Tumor MHC Class I Expression Associates with Intralesional IL2 Response in Melanoma

Cancer immunotherapy can result in lasting tumor regression, but predictive biomarkers of treatment response remain ill-defined. Here, we performed single-cell proteomics, transcriptomics, and genomics on matched untreated and IL2 injected metastases from patients with melanoma. Lesions that complet...

Descripción completa

Detalles Bibliográficos
Autores principales: Pourmaleki, Maryam, Jones, Caitlin J., Ariyan, Charlotte E., Zeng, Zheng, Pirun, Mono, Navarrete, Daniel A., Li, Yanyun, Zhang, Mianlei, Nandakumar, Subhiksha, Campos, Carl, Nadeem, Saad, Klimstra, David S., Temple-Oberle, Claire F., Brenn, Thomas, Lipson, Evan J., Schenk, Kara M., Stein, Julie E., Taube, Janis M., White, Michael G., Traweek, Raymond, Wargo, Jennifer A., Kirkwood, John M., Gasmi, Billel, Goff, Stephanie L., Corwin, Alex D., McDonough, Elizabeth, Ginty, Fiona, Callahan, Margaret K., Schietinger, Andrea, Socci, Nicholas D., Mellinghoff, Ingo K., Hollmann, Travis J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898286/
https://www.ncbi.nlm.nih.gov/pubmed/35013003
http://dx.doi.org/10.1158/2326-6066.CIR-21-1083

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898286/
https://www.ncbi.nlm.nih.gov/pubmed/35013003
http://dx.doi.org/10.1158/2326-6066.CIR-21-1083

Ejemplares similares